Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2004-09-01
This trial is conducted in Europe and the United States of America (USA). The purpose of this
study is to test whether insulin detemir is a safe and at least as effective alternative to
insulin glargine for the control of blood glucose in basal/bolus therapy in patients with
type I diabetes.
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2004-09-01
This trial is conducted in Europe and the United States of America (USA). The purpose of this
study is to test whether insulin detemir is a safe and at least as effective alternative to
insulin glargine for the control of blood glucose in basal/bolus therapy in patients with
type 2 diabetes.
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2005-02-01
This trial is conducted in Europe and the United States of America (USA). The aim of this
trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin
once a day (evening) when added to treatment with oral antidiabetic drugs in patients with
Type 2 diabetes.
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2005-03-01
This trial is conducted in the United States of America (USA). The purpose of this study is
to determine if the use of insulin detemir in combination with insulin aspart is safe and at
least as effective as insulin glargine in combination with insulin aspart for the control of
blood glucose in patients with Type 2 diabetes.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
